June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
|Articles|April 12, 2019
Screening for glaucoma: new strategies
L. Jay Katz, MD, delivered the Shaffer‐Hetherington‐Hoskins Lecture, "Screening for Glaucoma: New Strategies" at the 23rd annual Glaucoma 360 meeting at the Palace Hotel in San Francisco on Feb. 2, 2019. Here, he shares his take-home message for clinicians.
Advertisement
Dr. Katz delivered the ShafferâHetheringtonâHoskins Lecture, "Screening for Glaucoma: New Strategies" at the 23rd annual Glaucoma 360 meeting at the Palace Hotel in San Francisco on Feb. 2, 2019. Here, he shares his take-home message for clinicians.
Advertisement
Related to this article
Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.
A large real-world cohort study finds OSA is associated with elevated glaucoma risk, though whether positive airway pressure therapy itself plays a role remains unclear.
Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.
A retrospective study finds that direct selective laser trabeculoplasty significantly lowers intraocular pressure, with the greatest benefit seen in treatment-naive eyes.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA approves subcutaneous Enspryng for TED
2
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
3
OT Roundup: Optogenetics Nobel Prize, BRUNELLO, DRAGON, eye transplant
4
Introducing Noah Banoub: The medical student’s path from church pews to the retina clinic
5